Li Weng
Asuragen (United States)(US)Zhujiang Hospital(CN)
Publications by Year
Research Areas
Cancer Genomics and Diagnostics, Acute Myeloid Leukemia Research, Molecular Biology Techniques and Applications, Multiple Myeloma Research and Treatments, Lymphoma Diagnosis and Treatment
Most-Cited Works
- → Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma(2014)424 cited
- → Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma(2015)309 cited
- Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.(2001)
- → Identification of cyclin B1 and Sec62 as biomarkers for recurrence in patients with HBV-related hepatocellular carcinoma after surgical resection(2012)84 cited
- Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells.(1997)
- → Detection of circulating tumour DNA in patients with aggressive B‐cell non‐Hodgkin lymphoma(2013)71 cited
- → Functional characterization of uveal melanoma oncogenes(2020)69 cited
- → Deep Sequencing Reveals Myeloma Cells in Peripheral Blood in Majority of Multiple Myeloma Patients(2013)66 cited
- → A phase 2 study of Rituximab‐Bendamustine and Rituximab‐Cytarabine for transplant‐eligible patients with mantle cell lymphoma(2016)65 cited
- → Ginsenoside Rh1 potentiates dexamethasone’s anti-inflammatory effects for chronic inflammatory disease by reversing dexamethasone-induced resistance(2014)41 cited